Alithea Biotechnology GmbH - 12/02/2026 Intelligent immunotherapy – safety ensured Immunological cell fingerprints are Alithea Bio’s core expertise. The Freiburg-based company combines advanced molecular biology with cutting-edge IT and operates one of the world’s largest immunopeptidomics databases. Alithea Bio leverages this integrated platform to offer both contract research services and software-as-a-service solutions to develop safer and more precise personalised immunotherapies more quickly.
Rewriting the transcript to heal diseases - 29/01/2026 Therapy involving the umlauts of the genetic alphabet tRNAs are essential components of the protein synthesis machinery that also act as molecular switches in gene regulation and consequently in disease processes such as cancer. The Heidelberg-based start-up Umlaut.bio is developing novel therapeutics that specifically target tRNAs to intervene at the molecular origin of disease.
Press release - 13/05/2026 NVision Expands from Quantum Sensing to Quantum Computing to Accelerate Discovery and Validation of New Therapies NVision announced a $55 million Series B led by Abbott and unveiled PIQC, a new quantum computing platform built on its molecular quantum technology.
Press release - 05/09/2025 After EMBL: Umlaut.bio and its potential role in drug development Alumnus Bastian Linder discusses the origin of this start-up and how a tRNA mechanism is helping scientists understand the importance and use of various RNA modifications as they pertain to disease.
